Charting elimination in the pandemic: a SARS-CoV-2 serosurvey of blood donors in New Zealand

Carlton, Lauren H; Chen, Tiffany; Whitcombe, Alana L; McGregor, Reuben; Scheurich, Greg; Sheen, Campbell R.; Dickson, James M.; Bullen, Chris; Chiang, An‐Jen; Exeter, Daniel; Paynter, John; Baker, Michael G; Charlewood, Richard; Moreland, Nicole J.

doi:10.1017/s0950268821001643

Cited by 8 publications

(9 citation statements)

References 13 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This assay measures neutralising antibodies by quantifying the antibodies that block binding of the SARS-CoV-2 receptor binding domain to the hACE-receptor. Specificity was previously determined to be 100% using 413 local samples [11] . Sera was diluted 1:10 and the assay was performed following published protocols [12] , [13] .…”

Section: Laboratory Analysismentioning

confidence: 99%

Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults

Priddy

Williams²,

Carson³

et al. 2022

Vaccine

Self Cite

View full text Add to dashboard Cite

Section: Laboratory Analysismentioning

confidence: 99%

Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults

Priddy

Williams²,

Carson³

et al. 2022

Vaccine

Self Cite

View full text Add to dashboard Cite

“…This domain contains >90% of neutralising antibody epitopes -that is regions that block the entry of the virus into host cells via the hACE-2 receptor (6). Specificity was previously determined to be 100% using the 300 pre-pandemic ANS, as well as an additional 113 pre-pandemic samples (7).…”

mentioning

confidence: 99%

The Persistence of Neutralising Antibodies up to 11 months after SARS-CoV-2 Infection in the Southern Region of New Zealand

McGregor

Craigie

Jack

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

SummaryDuring the first wave of SARS-CoV-2 infection in New Zealand a cohort of 78 PCR-confirmed COVID-19 cases was recruited in the Southern District Health Board region. Here we report on this unique cohort nearly 1-year after infection. There was no known community transmission in the region over the study period due to New Zealand’s elimination status at the time, nor had any participants received a COVID-19 vaccine. In the absence of re-exposure, antibody reactivity to the viral spike protein, as well as neutralising antibodies to both the ancestral strain and the delta variant remained relatively stable between 8 and 11 months post-infection. This suggests long-lived antibody responses can be generated from a single natural infection event. However, given the risks of serious disease associated with SARS-CoV-2 infection, vaccination is still strongly recommended.

show abstract

“…This assay measures neutralising antibodies by quantifying the antibodies that block binding of the SARS-CoV-2 receptor binding domain to the hACE-receptor. Specificity was previously determined to be 100% using 413 local samples [11]. Sera was diluted 1:10 and the assay was performed following published protocols [12,13].…”

Section: Methodsmentioning

confidence: 99%

Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults

Priddy

Williams²,

Carson³

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

BackgroundThere is very little known about SARS-CoV-2 vaccine immune responses in New Zealand populations at greatest risk for serious COVID-19 disease.MethodsThis prospective cohort study assessed immunogenicity in BNT162b2 mRNA vaccine recipients in New Zealand without previous COVID-19, with enrichment for Māori, Pacific peoples, older adults ≥ 65 years of age, and those with co-morbidities. Serum samples were analysed at baseline and 28 days after second dose for presence of quantitative anti-S IgG by chemiluminescent microparticle immunoassay and for neutralizing capacity against Wuhan, Beta, Delta, and Omicron BA.1 strains using a surrogate viral neutralisation assay.Results285 adults with median age of 52 years were included. 55% were female, 30% were Māori, 28% were Pacific peoples, and 26% were ≥65 years of age. Obesity, cardiac and pulmonary disease and diabetes were more common than in the general population. All participants received 2 doses of BNT162b2 vaccine. At 28 days after second vaccination, 99.6% seroconverted to the vaccine, and anti-S IgG and neutralising antibody levels were high across gender and ethnic groups. IgG and neutralising responses declined with age. Lower responses were associated with age ≥75 and diabetes, but not BMI. The ability to neutralise the Omicron BA.1 variant in vitro was severely diminished but maintained against other variants of concern.ConclusionsVaccine antibody responses to BNT162b2 were generally robust and consistent with international data in this COVID-19 naïve cohort with representation of key populations at risk for COVID-19 morbidity. Subsequent data on response to boosters, durability of responses and cellular immune responses should be assessed with attention to elderly adults and diabetics.

show abstract

Charting elimination in the pandemic: a SARS-CoV-2 serosurvey of blood donors in New Zealand

Cited by 8 publications

References 13 publications

Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults

Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults

The Persistence of Neutralising Antibodies up to 11 months after SARS-CoV-2 Infection in the Southern Region of New Zealand

Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults

Contact Info

Product

Resources

About